Novartis Wins FDA Staff OK for Neupogen Biosimilar

Staff reviewers at the U.S. FDA recommended approval for a Novartis copy of an Amgen cancer treatment, Neupogen, a development that could make generic versions of complex biologic therapies more readily accessible in the U.S.



from WSJ.com: US Business http://ift.tt/1xL3PNc

via IFTTT